AOD-9604
Also known as: Anti-Obesity Drug 9604 · HGH Fragment 176-191
A modified fragment of human growth hormone (amino acids 176-191) that retains the fat-burning properties of HGH without its growth-promoting or diabetogenic effects.
Overview
AOD-9604 is a modified peptide fragment corresponding to amino acids 176-191 of human growth hormone, with an additional tyrosine residue at the N-terminus. It was specifically designed to isolate the fat-metabolizing properties of growth hormone while eliminating the growth-promoting effects and potential for insulin resistance. AOD-9604 stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation) through a mechanism that is distinct from the GH receptor — it does not bind to the GH receptor and does not increase IGF-1 levels. This means it promotes fat loss without the side effects associated with full GH therapy, such as insulin resistance, fluid retention, or acromegaly risk.
Clinical studies have shown modest but statistically significant fat loss with AOD-9604 compared to placebo. The peptide has also demonstrated cartilage repair properties, leading to its investigation as a treatment for osteoarthritis. In Australia, AOD-9604 has received GRAS (Generally Recognized As Safe) status from the TGA for use as a food supplement.
Mechanism of Action
Mimics the lipolytic action of the C-terminal fragment of growth hormone through a non-GH receptor mechanism. Stimulates beta-3 adrenergic receptor-mediated lipolysis. Inhibits lipogenic enzymes. Does not affect IGF-1, blood glucose, or tissue growth. Also stimulates proteoglycan and collagen synthesis in cartilage.
Key Benefits
Potential Side Effects
Common Stacks
This peptide is commonly combined with the following compounds for synergistic effects:
Known Interactions
The following interactions have been documented for AOD-9604. Always consult a healthcare professional before combining compounds.
Synergistic (2)
AOD-9604 targets fat metabolism directly (lipolysis) while semaglutide reduces appetite. Different mechanisms that can complement each other for fat loss.
AOD-9604 mobilizes fatty acids while L-Carnitine shuttles them into mitochondria for oxidation. Complementary fat-burning mechanisms.
Scientific References
Quick Reference
Typical Dose
300 mcg
Frequency
Once daily (morning, fasted)
Route
Subcutaneous injection
Half-Life
~1-2 hours
Cycle Length
12-20 weeks
FDA Status
Not FDA approved; GRAS status in Australia
Need to calculate dosing?
Use our reconstitution calculator to determine exact syringe measurements.
Open CalculatorThis information is for educational purposes only. Consult a qualified healthcare professional before using any peptide. Dosing information reflects commonly reported protocols and may not be appropriate for everyone.
Related Peptides in Fat Loss & Metabolic
Semaglutide
An FDA-approved GLP-1 receptor agonist that has revolutionized weight management, producing average weight loss of 15-17% of body weight in clinical trials.
Read moreTirzepatide
A first-in-class dual GIP/GLP-1 receptor agonist that has demonstrated the most potent weight loss results of any pharmaceutical agent, averaging 20-26% body weight reduction.
Read moreMOTS-c
A mitochondrial-derived peptide that acts as an exercise mimetic, improving metabolic homeostasis, insulin sensitivity, and reducing age-related metabolic decline.
Read more